52 related articles for article (PubMed ID: 23188538)
1. Expression of plasminogen activator inhibitor-2 is negatively associated with invasive potential in hepatocellular carcinoma cells.
Jin Y; Zhou L; Jin KM; Xing BC
Chin Med Sci J; 2013 Mar; 28(1):16-9. PubMed ID: 23527801
[TBL] [Abstract][Full Text] [Related]
2. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
Xu L; Wang P; Li L; Li L; Huang Y; Zhang Y; Zheng X; Yi P; Zhang M; Xu M
Mol Cancer; 2023 Oct; 22(1):174. PubMed ID: 37884951
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma.
Carr BI; Guerra V; Donghia R; Yilmaz S
J Gastrointest Cancer; 2021 Dec; 52(4):1340-1349. PubMed ID: 34611834
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract][Full Text] [Related]
5. Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas.
Ramnefjell M; Aamelfot C; Helgeland L; Akslen LA
Oncotarget; 2017 Oct; 8(53):90706-90718. PubMed ID: 29207598
[TBL] [Abstract][Full Text] [Related]
6. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Yin J; Bo WT; Sun J; Xiang X; Lang JY; Zhong JH; Li LQ
J Clin Transl Hepatol; 2017 Jun; 5(2):169-176. PubMed ID: 28660155
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Bae SY; Park HJ; Hong JY; Lee HJ; Lee SK
Sci Rep; 2016 Aug; 6():32258. PubMed ID: 27558531
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement.
Cheng S; Yang J; Shen F; Zhou W; Wang Y; Cong W; Yang GS; Cheng H; Hu H; Gao C; Guo J; Li A; Meng Y; Jiang X; Yang Y; Qian G; Luo M; Hu B; Man X; Zhang B; Su C; Zhou F; Li N; Shi J; Wang M; Zheng Y; Guo W; Sun J; Wang H; Lau WY; Wu MC
Oncotarget; 2016 Jun; 7(26):40816-40829. PubMed ID: 27027235
[TBL] [Abstract][Full Text] [Related]
9. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.
Cheng S; Chen M; Cai J;
Oncotarget; 2017 Jan; 8(5):8867-8876. PubMed ID: 27780939
[TBL] [Abstract][Full Text] [Related]
10. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.
Zhou L; Jin Y; Cui QC; Jin KM; Zhou WX; Xing BC
World J Surg; 2013 Mar; 37(3):608-13. PubMed ID: 23188538
[TBL] [Abstract][Full Text] [Related]
11. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma.
Lin T; Lin Z; Mai P; Zhang E; Peng L
Aging (Albany NY); 2021 Apr; 13(8):11786-11807. PubMed ID: 33878734
[TBL] [Abstract][Full Text] [Related]
13. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
14. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
Guo X; Xiong L; Zou L; Sun T; Zhang J; Li H; Peng R; Zhao J
Diagn Pathol; 2012 Aug; 7():96. PubMed ID: 22888955
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
